NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

NYSE issues a pre-market daily advisory direct from the trading floor.

The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on May 11th

  • Equities are lower Monday morning after President Trump called an Iranian counteroffer to end the conflict in the Middle East 'totally unacceptable.'
  • Intercontinental Exchange's (NYSE: ICE) Head of Mortgage and Housing Market Research Andy Walden will break down the May Mortgage Monitor on NYSE Live.
  • Eli Lilly (NYSE: LLY) CFO Lucas Montarce will join NYSE Live to discuss the company's latest milestone and takeaways from its recent earnings.
  • Once Upon a Farm's (NYSE: OFRM) behind-the-scenes footage of its February IPO will air on NYSE Live, providing viewers with new looks from the historic moment.  

Opening Bell
Eli Lilly (NYSE: LLY) celebrates its 150th anniversary of founding

Closing Bell
Darling Ingredients (NYSE: DAR) celebrates its Investor Day and path to long-term growth

For market insights, IPO activity, and today's opening bell, download the NYSE TV App: TV.NYSE.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-content-update-eli-lilly-to-celebrate-150-years-of-scientific-innovation-302768195.html

SOURCE New York Stock Exchange

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2026/11/c7380.html

News Provided by Canada Newswire via QuoteMedia

LLY
The Conversation (0)
Raptor Resources

Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada

Eastern Metals Ltd (ASX: EMS) (Eastern Metals or the Company) (to be renamed Raptor Metals Ltd (ASX: RAP)) is pleased to advise it has recommenced trading on the Australian Securities Exchange (ASX) today following its acquisition of Raptor Resources Limited (Raptor Resources). HIGHLIGHTS... Keep Reading...
Nextech3D.ai Poised for Growth as Event-Tech and 3D/AR Revenue Accelerates

Nextech3D.ai Poised for Growth as Event-Tech and 3D/AR Revenue Accelerates

Nextech3D.AI (CSE:NTAR,OTCQX:NEXCF,FSE:EP2) is gaining investor attention following H.C. Wainwright’s November 2025 coverage, highlighting renewed optimism about the company’s growth prospects, driven largely by its expanding event‑technology business.The analyst firm maintained a Buy rating... Keep Reading...
Lilly announces departure of Anat Ashkenazi, chief financial officer

Lilly announces departure of Anat Ashkenazi, chief financial officer

Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I would like to thank Anat for her 23 years of... Keep Reading...
Melissa Seymour to join Lilly as executive vice president of Global Quality

Melissa Seymour to join Lilly as executive vice president of Global Quality

Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 . Seymour currently serves as the chief quality officer for Bristol Myers Squibb and... Keep Reading...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development Eli Lilly and Company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News